Researchers' Broadening use of SiDMAP Technology Continues to Accelerate
News May 29, 2006
SiDMAP has reported that the pace at which institutions and researchers are adopting its proprietary metabolomics technology continues to accelerate, with six new project applications getting underway in the past five months.
SiDMAP recently has been hired to provide flux-based metabolomics data and analyses by researchers at BiPar Sciences, Inc. and two other major pharmaceutical companies as well as three extremely prestigious universities and leading healthcare centers.
Researchers at BiPar Sciences, Inc. led by Valeria Ossovskya, Ph.D. Associate Director, Pre-Clinical Development, are working with SiDMAP to gather metabolic flux information on a proprietary therapeutic compound BiPar is developing.
An in vitro study was performed and the initial results were provided to Dr. Ossovskya in two weeks.
"As a result of SiDMAP's work we have gained greater insight into this compound's mechanism of action," Dr. Ossovskya commented. "Their professionalism and effort exceeded our expectations."
"The fact that companies like BiPar and such prestigious academic institutions and health centers have chosen to work with SiDMAP merely reaffirms our belief that the quality and unique nature of the data we provide truly distinguish us from other metabolomic solution providers," said Agi Hirshberg, SiDMAP's President and Founder.
"In addition to these new customers, we are extremely proud that most of our initial customers are returning for additional projects and many are actively considering broader collaborations with us. When customers sign up for second and third projects, it truly validates the utility of our services."
SiDMAP is honoring the requests of the two other companies and three academic institutions to abstain from disclosing their identities and any of the financial terms of the agreements between the parties.
Scientists from the UNC School of Medicine discovered that the anti-inflammatory protein NLRP12 normally helps protect mice against obesity and insulin resistance when they are fed a high-fat diet. The researchers also reported that the NLRP12 gene is underactive in people who are obese, making it a potential therapeutic target for treating obesity and diabetes.READ MORE
Nonalcoholic fatty liver disease produces no noticeable symptoms, but one out of every five people with it will go on to develop a more serious conditions such as nonalcoholic steatohepatosis and cirrhosis. Three new studies investigate how mitochondrial energy production is altered by the progress of fatty liver disease.READ MORE